- Home
- BCAB
BCAB
BioAtla Inc.
as 07-26-2024 4:00pm EST
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 81.8M | IPO Year: | 2020 |
| Target Price: | $12.75 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $4.02 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of BioAtla Inc. (BCAB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MCBRINN SYLVIA | BCAB | Director | Dec 26 '23 | Buy | $2.33 | 4,000 | $9,320.00 | 15,125 | SEC Form 4 |
| SHORT JAY M PHD | BCAB | Chief Executive Officer | Dec 20 '23 | Buy | $2.14 | 50,000 | $106,910.00 | 1,439,283 | SEC Form 4 |
| STEINMAN LAWRENCE | BCAB | Director | Dec 19 '23 | Buy | $2.05 | 20,000 | $41,048.00 | 38,459 | SEC Form 4 |
| Vasquez Christian | BCAB | See Remarks | Dec 19 '23 | Buy | $2.04 | 7,495 | $15,262.07 | 115,659 | SEC Form 4 |
| MCBRINN SYLVIA | BCAB | Director | Mar 28 '23 | Buy | $2.35 | 4,000 | $9,400.00 | 19,125 | SEC Form 4 |
Latest BioAtla Inc. News
BCAB Breaking Stock News: Dive into BCAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
Pharmaceutical Technology
2 days ago
BioAtla receives FDA fast track designation for ozuriftamab vedotin
MT Newswires
3 days ago
BioAtla's Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
GlobeNewswire
3 days ago
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Simply Wall St.
24 days ago
Insider Traders Lose US$67k As BioAtla Drops
GlobeNewswire
a month ago
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
Compare BCAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCAB BioAtla Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.